Publication 2025
448.
Fatima Y, Jobre KN, Gomez-Gomez E, Małkiewicz B, Vlahou A, Mokou M, Mischak H, Frantzi M, Jankowski V.
Omics-Mediated Treatment for Advanced Prostate Cancer: Moving Towards Precision Oncology
Int J Mol Sci. 2025, 26(15):7475.
447.
Devos H, Mina IK, Paradeisi F, Makridakis M, Tserga A, Mokou M, Zoidakis J, Mischak H, Vlahou A, Latosinska A, Roubelakis MG.
A Naturally Occurring Urinary Collagen Type I Alpha 1-Derived Peptide Inhibits Collagen Type I-Induced Endothelial Cell Migration at Physiological Concentrations
Int J Mol Sci. 2025, 26(15):7480.
446.
An DW, Mokwatsi GG, Zhang DY, Martens DS, Yu YL, Chori BS, Odili AN, Kruger R, Gafane-Matemane LF, Siwy J, Latosinska A, Mischak H, Mels CM, Schutte AE, M'Buyamba-Kabangu JR, Nawrot TS, Li Y, Staessen JA.
Evaluation of race-free eGFR equations in individuals of different ethnicity
Blood Press. 2025, 15:1-17. Online ahead of print.
445.
Törnhage CJ, Peters B, Latosinska A, Mina IK, Mokou M, Mischak H, Siwy J.
Establishment of a Protocol for CE-MS Based Peptidome Analysis of Human Saliva
Proteomics. 2025, 25(13):e00231. Epub 2025 May 27.
444.
Frantzi M, Keller F, Latosinska A, Beige J, Mebazaa A, Caillard A, An DW, Perco P, Schanstra JP, Catanese L, Wendt R, Rupprecht H, Staessen JA, Vlahou A, Mischak H, Siwy J.
Urinary collagen peptides predict mortality
medRxiv 2025.06.05.25329025
443.
Biglari S, Mischak H, Beige J, Latosinska A, Siwy J, Banasik M.
The Future of Chronic Kidney Disease Treatment: Combination Therapy (Polypill) or Biomarker-Guided Personalized Intervention?
Biomolecules. 2025, 15(6):809.
442.
Roa FJ, Roubelakis M, Paschidis K, van Creij NCH, Handle F, Makridakis M, Narayanasamy S, Balaur IA, Tserga A, Vlahou A, Santer FR, Holm PS, Hoffmann M, Puhr M, Mokou M, Frantzi M, Schneider R, Latosinska A, Mischak H, Satagopam V, Culig Z, Pichler R.
Repurposing Amiodarone for Bladder Cancer Treatment.
Cancer Res Commun. 2025, 5(6):906-920.
441.
Schork A, Fritsche A, Schleicher ED, Peter A, Heni M, Stefan N, von Schwartzenberg RJ, Guthoff M, Mischak H, Siwy J, Birkenfeld AL, Wagner R.
Differential risk assessment in persons at risk of type 2 diabetes using urinary peptidomics
Metabolism. 2025, 167:156174. Epub 2025 Feb 27.
440.
Mina IK, Iglesias-Martinez LF, Ley M, Fillinger L, Perco P, Siwy J, Mischak H, Jankowski V.
Investigation of the Urinary Peptidome to Unravel Collagen Degradation in Health and Kidney Disease
Proteomics. 2025, 25(11-12):e202400279. Epub 2024 Dec 30.
439.
Plas S, Melchior F, Aigner GP, Frantzi M, Pencik J, Kafka M, Heidegger I.
The impact of urine biomarkers for prostate cancer detection - A systematic state of the art review
Crit Rev Oncol Hematol. 2025, 210:104699. Epub 2025 Mar 17.
438.
Glorieux G, Klein J, Latosinska A.
Multi-Disciplinary and Omics-Driven Approaches to Advance Personalized Medicine in Cardiovascular and Chronic Kidney Disease
Proteomics. 2025, 25(11-12):e00093.
437.
An DW, Martens DS, Mokwatsi GG, Yu YL, Chori BS, Latosinska A, Isiguzo G, Eder S, Zhang DY, Mayer G, Kruger R, Brguljan-Hitij J, Delles C, Mels CMC, Stolarz-Skrzypek K, Rajzer M, Verhamme P, Schutte AE, Nawrot TS, Li Y, Mischak H, Odili AN, Staessen JA.
Urinary Proteomics and Systems Biology Link Eight Proteins to the Higher Risk of Hypertension and Related Complications in Blacks Versus Whites
Proteomics. 2025, 25(11-12):e202400207. Epub 2024 Nov 24.
436.
Heidegger I, Frantzi M, Salcher S, Tymoszuk P, Martowicz A, Gomez-Gomez E, Blanca A, Lendinez Cano G, Latosinska A, Mischak H, Vlahou A, Langer C, Aigner F, Puhr M, Krogsdam A, Trajanoski Z, Wolf D, Pircher A.
Prediction of Clinically Significant Prostate Cancer by a Specific Collagen-related Transcriptome, Proteome, and Urinome Signature
Eur Urol Oncol. 2025, 8(3):652-662. Epub 2024 Jun 8.
435.
Martin EM, Genovese F, Mischak H, Siwy J, Rupprecht H, Catanese L, Latosinska A.
Association of Urinary Collagen Type III Degradation Product With Kidney Function and Fibrosis in Chronic Kidney Disease Patients
Proteomics. 2025, 25(11-12):e202400354. Epub 2025 Apr 10.
434.
Latosinska A, Mischak H, Vlahou A.
From Discovery to Implementation: Bringing Proteomics to the Clinic
Proteomics. 2025 May; 20:e202500017. Online ahead of print.
433.
Frantzi M, Tymoszuk P, Salcher S, Gomez-Gomez E, Morillo AC, Melchior F, Blanca A, Mischak H, Vlahou A, Pircher A, Heidegger I.
Prediction of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy by Collagen Models Using Multiomic Profiles
Eur Urol Oncol. 2025 Apr 30:S2588-9311(25)00094-X. Online ahead of print.
432.
Gregorich M, Kammer M, Mischak H, Heinze G.
Prediction Modeling With Many Correlated and Zero-Inflated Predictors: Assessing the Nonnegative Garrote Approach
Stat Med. 2025, 44(8-9):e70062.
431.
Burgmaier K, Buffin-Meyer B, Klein J, Becknell B, McLeod D, Boeckhaus J, Gross O, Dafinger C, Siwy J, Decramer S, Schaefer F, Liebau MC, Schanstra JP.
Urinary peptide signature distinguishes autosomal recessive polycystic kidney disease from other causes of chronic kidney disease
Clin Kidney J. 2025, 18(5):sfaf093. eCollection 2025 May.
430.
Mischak H, Schanstra JP, Vlahou A, Beige J.
Clinical Proteomics, Quo Vadis?
Proteomics. 2025, 25(7):e202400346. Epub 2025 Feb 9
429.
Yu YL, An DW, Chori BS, Kaleta BP, Mokwatsi G, Martens DS, Abiodun OO, Anya T, Łebek-Szatańska A, Yeh JS, Mels CMC, Latosinska A, Kruger R, Isiguzo G, Narkiewicz K, Shehu MN, Salazar M, Espeche W, Mujaj B, Brgulian-Hitij J, Olszanecka A, Wojciechowska W, Reyskens P, Rajzer M, Januszewicz A, Stolarz-Skrzypek K, Asayama K, Allegaert K, Verhamme P, Mischak H, Nawrot TS, Odili AN, Staessen JA; UPRIGHT-HTM investigators.
Racial and regional disparities in the risk of noncommunicable disease between sub-Saharan black and European white patients
J Hypertens. 2025, 43(3):481-491. Epub 2024 Nov 21.
428.
Latosinska A, Mina IK, Thi Minh NN, Golovko I, Keller F, Mayer G, Rossing P, Staessen JA, Delles C, Beige J, Glorieux G, Clark AL, Schanstra JP, Vlahou A, Peter K, Rychlík I, Ortiz A, Campbell A, Rupprecht H, Persson F, Mischak H, Siwy J.
In silico prediction of optimal multifactorial intervention in CKD
medRxiv 2025.02.14.25322292
427.
Aktas G, Keller F, Siwy J, Latosinska A, Mischak H, Mayor J, Clausen J, Wilhelmi M, Brauckmann V, Sehmisch S, Pacha TO.
Application of urinary peptide-biomarkers in trauma patients as a predictive tool for prognostic assessment, treatment and intervention timing
Sci Rep. 2025, 15(1):898.
426.
Frantzi M, Morillo AC, Lendinez G, Blanca A, Lopez Ruiz D, Parada J, Heidegger I, Culig Z, Mavrogeorgis E, Beltran AL, Mora-Ortiz M, Carrasco-Valiente J, Mischak H, Medina RA, Campos Hernandez P, Gómez Gómez E.
Validation of a Urine-Based Proteomics Test to Predict Clinically Significant Prostate Cancer: Complementing mpMRI Pathway
Pathobiology 2025; 92(2):99-108. Epub 2024 Nov 11.
425.
Wasehuus V, Rotbain Curovic V, Tofte N, Lindhardt M, Currie G, Delles C, Frimodt-Møller M, Mischak H, von der Leyen H, Hansen TW, Kümler T, Persson F, Rossing P; PRIORITY Study group.
Effect of spironolactone wash-out on albuminuria after long-term treatment in individuals with type 2 diabetes and high risk of kidney disease-An observational follow-up of the PRIORITY study
Diabetes Obes Metab. 2025, 27(1):387-393. Epub 2024 Oct 28.